成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 147403-03-0 Chemical Structure| 147403-03-0

Structure of Azilsartan
CAS No.: 147403-03-0

Chemical Structure| 147403-03-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 147403-03-0

,{[proInfo.pro_purity]}

Azilsartan is an orally available angiotensin II type 1 (AT1) receptor antagonist with IC50 value of 2.6 nM.

Synonyms: TAK-536

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Azilsartan

CAS No. :147403-03-0
Formula : C25H20N4O5
M.W : 456.45
SMILES Code : O=C(C1=C2N(CC3=CC=C(C4=CC=CC=C4C5=NC(ON5)=O)C=C3)C(OCC)=NC2=CC=C1)O
Synonyms :
TAK-536
MDL No. :MFCD20278186
InChI Key :KGSXMPPBFPAXLY-UHFFFAOYSA-N
Pubchem ID :135415867

Safety of Azilsartan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H361-H413
Precautionary Statements:P501-P273-P202-P201-P280-P308+P313-P405

Related Pathways of Azilsartan

GPCR

Isoform Comparison

Biological Activity

Target

  • AT1 receptor

    AT1 receptor, IC50:2.6 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Osteoclast precursors 0, 0.01, 0.1, 1, 10 μM 5 days To evaluate the effect of Azilsartan on RANKL-induced osteoclastogenesis. Results showed that Azilsartan did not significantly inhibit RANKL-induced osteoclastogenesis. PMC10545845
Osteoblasts 1 μM 3 days To evaluate the effect of Azilsartan on LPS-induced RANKL expression. Results showed that Azilsartan had no significant effect on LPS-induced RANKL mRNA and protein expression. PMC10545845
Macrophages 1 μM 3 days Inhibited migration of macrophages toward MCP-1 PMC10545845
BEnd.3 brain endothelial cells 3 μM and 6 μM 24 hours Azilsartan significantly alleviated high glucose-induced endothelial monolayer permeability and decreased occludin expression PMC8806574
MLO-Y4 cells 10^-7 M 48 hours To evaluate the effect of Azilsartan on Ang II-induced RANKL and M-CSF mRNA expression. Results showed that Azilsartan significantly inhibited the upregulation of RANKL and M-CSF mRNA expression induced by Ang II. PMC11853621

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL6/J mice LPS-induced inflammatory bone resorption model 100 μg/day Subcutaneous injection Once daily for 5 consecutive days To evaluate the effect of Azilsartan on LPS-induced bone resorption and osteoclastogenesis. Results showed that Azilsartan significantly inhibited LPS-induced bone resorption and osteoclastogenesis, and reduced the mRNA expression levels of TRAP, cathepsin K, RANKL, and TNF-α. PMC10545845
C57BL/6J mice Ovariectomy (OVX)-induced osteoporosis model 1 mg/kg and 3 mg/kg Oral gavage Twice a week for 6 weeks To evaluate the protective effect of Azilsartan on OVX-induced osteoporosis. Results showed that Azilsartan significantly ameliorated OVX-induced bone loss and decreased ROS levels. PMC8662525
Male db/db mice Diabetes model 20 μg/day 10 consecutive days Azilsartan dramatically reversed increased BBB permeability, suppressed occludin expression, excessive release of inflammatory factors, and downregulation of KLF2 in diabetic mice PMC8806574

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01715584 Hypertension Phase 4 Recruiting December 31, 2019 Canada, Ontario ... More >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD ?? 519 685 8500 ext 58525 ?? Craig.Railton@lhsc.on.ca ?? Principal Investigator: Craig J Railton, MD, PhD ?? ?? ?? Sub-Investigator: Jonathan Fairbairn, BSc ?? ?? ?? Sub-Investigator: George Nicoloau, MD ?? ?? ?? Sub-Investigator: Robert Gros, PhD ?? ?? ?? Sub-Investigator: Jason Franklin, MD ?? ?? ?? Sub-Investigator: John Yoo, MD ?? ?? ?? Sub-Investigator: Kevin Fung, MD ?? ?? ?? Sub-Investigator: Anthony Nichols, MD ?? ?? ?? Sub-Investigator: Danielle McNeil, MD Less <<
NCT02235909 Hypertension Phase 3 Recruiting August 2020 -
NCT00362115 Hypertension Phase 2 Completed - -
NCT03006796 - Recruiting June 2019 Russian Federation ... More >> City Hospital №5 Recruiting Moscow, Russian Federation, 107015 Contact: Elena Y Shupenina, PhD ?? +74992684459 Less <<
NCT00759551 Hypertension Phase 2 Completed - -
NCT00362115 - Completed - -
NCT00762736 Diabetes Mellitus Phase 2 Completed - -
NCT00376181 Type 2 Diabetes Phase 3 Terminated(Combination formula... More >>tion concerns) Less << - -
NCT00696436 Hypertension Phase 3 Completed - -
NCT00847626 - Completed - -
NCT00847626 Hypertension Phase 3 Completed - -
NCT01289132 Essential Hypertension Phase 2 Completed - -
NCT02100319 Hypertension COMPLETED 2016-02-29 Osaka, Japan|Tokyo, Japan
NCT00696241 Hypertension Phase 3 Completed - -
NCT02348658 Hypertension Phase 1 Completed - Japan ... More >> Fukuoka-shi, Fukuoka, Japan Less <<
NCT02348658 - Completed - -
NCT00696436 - Completed - -
NCT02401464 - Completed - -
NCT02401464 Japanese Healthy Adult Males Phase 1 Completed - Japan ... More >> Kagoshima, Japan Less <<
NCT02277691 Essential Hypertension Phase 3 Completed - Japan ... More >> Nagoya-shi, Aichi, Japan Chiba-shi, Chiba, Japan Itojima-shi, Fukuoka, Japan Kouriyama-shi, Fukushima, Japan Sapporo-shi, Hokkaido, Japan Amagasaki-shi, Hyougo, Japan Tsukuba-shi, Ibaragi, Japan Morioka-shi, Iwate, Japan Sakaide-shi, Kagawa, Japan Takamatsu-shi, Kagawa, Japan Kawasaki-shi, Kanagawa, Japan Kyoto-shi, Kyoto, Japan Uji-shi, Kyoto, Japan Sendai-shi, Miyagi, Japan Hirakata-shi, Osaka, Japan Osaka-shi, Osaka, Japan Takatsuki-shi, Osaka, Japan Saitama-shi, Saitama, Japan Tokorozawa-shi, Saitama, Japan Yaizu-shi, Shizuoka, Japan Chiyoda-ku, Tokyo, Japan Choufu-shi, Tokyo, Japan Kodaira-shi, Tokyo, Japan Koutou-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Choufu-shi, Japan Kawasaki-shi, Japan Koutou-ku, Japan Morioka-shi, Japan Sakaide-shi, Japan Setagaya-ku, Japan Shinagawa-ku, Japan Shinjuku-ku, Japan Tsukuba-shi, Japan Uji-shi, Japan Yaizu-shi, Japan Less <<
NCT00591266 Hypertension Phase 3 Completed - -
NCT00696241 - Completed - -
NCT02277691 - Completed - -
NCT00591773 Hypertension Phase 3 Completed - -
NCT00591266 - Completed - -
NCT00760214 Hypertension Phase 3 Completed - -
NCT01124656 Diabetes Mellitus, Type 2 Phase 3 Terminated(Formulation issues.... More >>) Less << - -
NCT00591773 - Completed - -
NCT00760214 - Completed - -
NCT01078376 Hypertension Phase 1 Terminated(Business Decision (... More >>see below)) Less << - United States, Arkansas ... More >> Little Rock, Arkansas, United States United States, Georgia Atlanta, Georgia, United States United States, Kentucky Louisville, Kentucky, United States United States, Ohio Toledo, Ohio, United States United Kingdom Birmingham, England, United Kingdom Bristol, England, United Kingdom London, England, United Kingdom Manchester, England, United Kingdom Less <<
NCT00696384 Hypertension Phase 3 Completed - -
NCT01078376 - Terminated(Business Decision (... More >>see below)) Less << - -
NCT00696384 - Completed - -
NCT00846365 - Completed - -
NCT00591253 Hypertension Phase 3 Completed - -
NCT00846365 Essential Hypertension Phase 3 Completed - -
NCT01985152 Health Phase 1 Unknown - China ... More >> TEDA International Cardiovascular Hospital Recruiting Tianjin, China Contact: Jie Hou, Associate Chief Physician ?? 86-022-65209939 ?? ?? Principal Investigator: Jie Hou, Associate Chief Physician Less <<
NCT00591578 Hypertension Phase 3 Completed - -
NCT00591578 - Completed - -
NCT02072330 Grade I or II Essential Hypert... More >>ension Less << Phase 2 Phase 3 Completed - Japan ... More >> Touon-shi, Ehime, Japan Fukuoka-shi, Fukuoka, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-shi, Hokkaido, Japan Hanamaki-shi, Iwate, Japan Morioka-shi, Iwate, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Sendai-shi, Miyagi, Japan Osaka-shi, Osaka, Japan Suita-shi, Osaka, Japan Shinjuku-ku, Tokyo, Japan Toyama-shi, Toyama, Japan Less <<
NCT00996281 - Completed - -
NCT01309828 - Completed - -
NCT00591253 - Completed - -
NCT00996281 Essential Hypertension Phase 3 Completed - Austria ... More >> Graz, Styria, Austria Germany Karlsruhe, Baden-Wurttemberg, Germany Hannover, Lower Saxony, Germany Kiel-Kronshagen, Schleswig-Holstein, Germany Netherlands Breda, North Brabant, Netherlands Eindhoven, North Brabant, Netherlands Amsterdam, North Holland, Netherlands Velp, Rheden, Netherlands Leiderdorp, South Holland, Netherlands Zoetermeer, South Holland, Netherlands Rotterdam, Zuid-Holland, Netherlands Groningen, Netherlands Poland Bydgoszcz, Kuyavian-Pomeranian, Poland Skierniewice, L0dz, Poland Zgierz, L0dz, Poland Gdansk, Pomeranian, Poland Gdynia, Pomeranian, Poland Sopot, Pomeranian, Poland Mikolow, Silesian, Poland United Kingdom Avon, England, United Kingdom Bolton, England, United Kingdom Chorley, England, United Kingdom Inverness, England, United Kingdom Liverpool, England, United Kingdom Surrey, England, United Kingdom Warwickshire, England, United Kingdom Less <<
NCT00695955 Hypertension Phase 3 Completed - -
NCT01033071 Essential Hypertension Phase 3 Completed - -
NCT01609959 Hypertension Phase 4 Completed - Japan ... More >> First Department of Nara Medical University Kashihara, Nara, Japan, 634-8522 Less <<
NCT01033071 - Completed - -
NCT01309828 Safety Phase 3 Completed - -
NCT00695955 - Completed - -
NCT02786082 Hypertension Phase 1 Completed - -
NCT02079805 Essential Hypertension Complic... More >>ated by Type 2 Diabetes Mellitus Less << Phase 4 Completed - Japan ... More >> Kyoto-Shi, Kyoto, Japan Less <<
NCT02079805 - Completed - -
NCT01496430 Hypertension ... More >>Diabetes Less << Phase 3 Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns. (See below)) Less << - -
NCT02609490 Hypertension Phase 3 Completed - China ... More >> Peking University First hospiatl Beijing, China, 100000 Less <<
NCT02407210 Essential Hypertension Phase 3 Unknown - China ... More >> Beijing ANZHEN Hospital Recruiting Beijing, China, 100029 Contact: Changsheng Ma, Professor ?? 86-010-64456078 ?? chshma@vip.sina.com ?? Principal Investigator: Changsheng Ma, Professor Less <<
NCT00818883 Essential Hypertension Phase 3 Completed - -
NCT02181816 - Completed - Japan ... More >> Osaka, Japan Tokyo, Japan Less <<
NCT01762501 Hypertension Not Applicable Completed - -
NCT01762501 - Completed - -
NCT02541669 Healthy Volunteer Phase 1 Completed - China, Beijing,P.R. ... More >> Beijing, Beijing,P.R., China Less <<
NCT00818883 - Completed - -
NCT03042299 - Completed - -
NCT01456169 Essential Hypertension Phase 3 Completed - -
NCT02791438 Pediatric Hypertension Phase 3 Active, not recruiting June 11, 2019 Japan ... More >> Nagakute, Aichi, Japan Nagoya, Aichi, Japan Obu, Aichi, Japan Sapporo, Hokkaido, Japan Kobe, Hyogo, Japan Kanazawa, Ishikawa, Japan Yokohama, Kanagawa, Japan Nankoku, Kochi, Japan Sendai, Miyagi, Japan Shimajiri-gun, Okinawa, Japan Izumi, Osaka, Japan Osaka Sayama, Osaka, Japan Otsu, Shiga, Japan Shimotsuke, Tochigi, Japan Fuchu, Tokyo, Japan Nerima-ku, Tokyo, Japan Ota-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Akita, Japan Chiba, Japan Fukuoka, Japan Fukushima, Japan Hiroshima, Japan Niigata, Japan Okayama, Japan Osaka, Japan Saitama, Japan Shizuoka, Japan Wakayama, Japan Less <<
NCT01496430 - Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns. (See below)) Less << - -
NCT01456169 - Completed - -
NCT03434977 Healthy Volunteers PHASE1 COMPLETED 2018-03-11 Fukuoka Mirai Hospital, Fukuok... More >>a, Japan Less <<
NCT02092025 Hypertension COMPLETED 2016-01-15 Osaka, Japan|Tokyo, Japan
NCT03042299 Japanese Healthy Adult Male Pa... More >>rticipants Less << Phase 1 Completed - Japan ... More >> Nishi Kumamoto Hospital Kumamoto, Japan Less <<
NCT02480764 Essential Hypertension Phase 3 Completed - -
NCT02203916 - Completed - -
NCT02400775 Essential Hypertension With St... More >>able Angina and Dyslipidemia Less << PHASE4 WITHDRAWN 2025-04-16 Tokushima, Japan
NCT03539627 - Not yet recruiting June 2021 -
NCT01774591 Hypertension Not Applicable Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT02203916 Hypertension Phase 3 Completed - Korea, Republic of ... More >> Chuncheon-Si, Gangwon-do, Korea, Republic of Wonju-Si, Gangwon-do, Korea, Republic of Anyang-si, Gyeonggi-do, Korea, Republic of Goyang-si, Gyeonggi-do, Korea, Republic of Seongnam-si, Gyeonggi-do, Korea, Republic of Suwon-si, Gyeonggi-do, Korea, Republic of Daegu, Gyeongsangbuk-do, Korea, Republic of Yangsan-si, Gyeongsangnam-do, Korea, Republic of Jeonju-si, Jeollabuk-do, Korea, Republic of Gwangju, Jeollanam-do, Korea, Republic of Busan, Korea, Republic of Daegu, Korea, Republic of Daejeon, Korea, Republic of Incheon, Korea, Republic of Seoul, Korea, Republic of Less <<
NCT02235519 Hypertension ... More >>Obesity Type 2 Diabetes Mellitus Less << Phase 2 Phase 3 Unknown June 2015 Mexico ... More >> Hospital General de Mexico "Dr. Eduardo Liceaga" Recruiting Mexico, Mexico, D.F., Mexico, 06720 Contact: Juan A Peralta, bachelor Less <<
NCT02756819 - Completed - -
NCT02451150 Pediatric Hypertension PHASE3 COMPLETED 2025-09-15 Fuchu, Japan|Oofu, Japan|Setag... More >>aya-ku, Japan Less <<
NCT03652792 Bioequivalence of Two Azilsart... More >>an Formulations Less << Phase 1 Completed - Hong Kong ... More >> Phase I Clinical Trial Centre, Chinese University of Hong Kong Hong Kong, Sha Tin New Territories, Hong Kong, 000000 Less <<
NCT02451150 Pediatric Hypertension PHASE3 COMPLETED 2025-09-15 Fuchu, Japan|Oofu, Japan|Setag... More >>aya-ku, Japan Less <<
NCT01774591 - Completed - -
NCT02517866 Essential Hypertension ... More >> Type 2 Diabetes Mellitus Less << Phase 4 Completed - China, Hong Kong ... More >> Hong Kong, Hong Kong, China Taiwan Changhua county, Taiwan Kaohsiung City, Taiwan Kaohsiung, Taiwan Taichung, Taiwan Tainan City, Taiwan Taipei, Taiwan Taoyuan County, Taiwan Thailand Bangkok, Thailand Chiang Mai, Thailand Khon Kaen, Thailand Pathumtani, Thailand Less <<
NCT04668157 Hypertension PHASE3 COMPLETED 2023-12-28 Japanese Red Cross Aichi Medic... More >>al Center Nagoya Daini Hospital, Nagoya, Aichi, Japan|Aichi Children's Health and Medical Center, Obu, Aichi, Japan|Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Miyagi Children's Hospital, Sendai, Miyagi, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|University of the Ryukyus Hospital, Nakagami-gun, Okinawa, Japan|Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Shimajiri-gun, Okinawa, Japan|Osaka University Hospital, Suita, Osaka, Japan|Shiga University of Medical Science Hospital, Otsu, Shiga, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Hiroshima Prefectural Hospital, Hiroshima, Japan|Local Independent Administrative Institution Saitama prefectural hospital organization Saitama Children's Medical Center, Saitama, Japan|Shizuoka Childrens Hospital, Shizuoka, Japan|Wakayama Medical University Hospital, Wakayama, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.95mL

2.19mL

1.10mL

21.91mL

4.38mL

2.19mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories